Chong Kun Dang Reports Q3 Operating Profit of 53.1 Billion KRW, Up 34% Year-on-Year

Jongkundang announced on the 27th that its individual-based operating profit for the third quarter of this year was tentatively estimated at 53.072 billion KRW, a 33.8% increase compared to the same period last year.

Jongkundang Headquarters Building.
[Photo by Jongkundang]

During the same period, sales increased by 4.1% from the same period last year to 396.211 billion KRW, and net profit rose by 49% to 43.511 billion KRW.

Looking at the individual-based performance on a cumulative basis for the third quarter, sales increased by 6% compared to the same period last year to 1.1482 trillion KRW, and operating profit grew by 37.4% to 126.524 billion KRW.

A Jongkundang official explained, "Existing products such as Prolia, Dilatrin, Gliatilin, and Benfobel, as well as new products like Lucenbess, Exigluess, and the Vital Program Vitamin C, all showed balanced growth, driving the overall performance."

This content was produced with the assistance of AI translation services.